无敌金刚。
The six million dollar man.
作者信息
Volpato Mathilde, Nowak Stefan, Bourrain Jean Luc, Demoly Pascal, Ahmed Engi, Bourdin Arnaud, Charriot Jeremy
机构信息
Dept of Respiratory Diseases, University of Montpellier, Montpellier, France.
出版信息
ERJ Open Res. 2021 Jan 18;7(1). doi: 10.1183/23120541.00341-2020. eCollection 2021 Jan.
Abstract
摘要
https://bit.ly/2GykNtI. （此为链接，无法准确翻译为中文，保留原文即可）
相似文献
1
The six million dollar man.无敌金刚。
ERJ Open Res. 2021 Jan 18;7(1). doi: 10.1183/23120541.00341-2020. eCollection 2021 Jan.
2
Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study.加拿大美泊利单抗的治疗时间及合并用药情况：一项回顾性队列研究。
ERJ Open Res. 2021 Mar 29;7(1). doi: 10.1183/23120541.00778-2020. eCollection 2021 Jan.
3
Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study.在开始使用生物制剂之前哮喘患者的疾病负担：一项回顾性队列数据库研究。
Allergy Asthma Proc. 2019 May 1;40(3):146-153. doi: 10.2500/aap.2019.40.4220. Epub 2019 Mar 29.
4
Effectiveness and safety of Omalizumab in the treatment of chronic spontaneous urticaria: Systematic review and meta-analysis.奥马珠单抗治疗慢性自发性荨麻疹的有效性和安全性：系统评价与荟萃分析。
Allergol Immunopathol (Madr). 2019 Nov-Dec;47(6):515-522. doi: 10.1016/j.aller.2019.05.003. Epub 2019 Oct 11.
5
The economic cost of sleep disorders.睡眠障碍的经济成本。
Sleep. 2006 Mar;29(3):299-305. doi: 10.1093/sleep/29.3.299.
6
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.美泊利单抗或安慰剂用于嗜酸性肉芽肿性多血管炎
N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079.
7
Return of the six million dollar man.
Hosp Pract. 1979 Apr;14(4):171-2. doi: 10.1080/21548331.1979.11707534.
8
Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.靶向嗜酸性粒细胞性哮喘中的白细胞介素-5通路：美泊利单抗与贝那利珠单抗在外周血嗜酸性粒细胞计数降低方面的比较。
Allergy Asthma Clin Immunol. 2021 Jan 6;17(1):3. doi: 10.1186/s13223-020-00507-0.
9
[The Six Million Dollar Man: from fiction to reality].
Ned Tijdschr Geneeskd. 2013;157(52):A7055.
10
New biologics in the treatment of urticaria.治疗荨麻疹的新型生物制剂。
Curr Opin Allergy Clin Immunol. 2018 Oct;18(5):425-431. doi: 10.1097/ACI.0000000000000466.
引用本文的文献
1
Combination of Biological Therapy in Severe Asthma: Where We Are?重度哮喘生物治疗的联合应用：我们目前的进展如何？
J Pers Med. 2023 Nov 10;13(11):1594. doi: 10.3390/jpm13111594.
2
The use of biologics in personalized asthma care.生物制剂在个体化哮喘治疗中的应用。
Expert Rev Clin Immunol. 2021 Dec;17(12):1301-1309. doi: 10.1080/1744666X.2021.2006635. Epub 2021 Nov 23.
本文引用的文献
1
Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria.度普利尤单抗作为治疗难治性慢性自发性荨麻疹的新型疗法。
J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1659-1661.e1. doi: 10.1016/j.jaip.2018.11.018. Epub 2018 Nov 27.
2
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.度普利尤单抗治疗糖皮质激素依赖型重症哮喘的疗效和安全性。
N Engl J Med. 2018 Jun 28;378(26):2475-2485. doi: 10.1056/NEJMoa1804093. Epub 2018 May 21.
3
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.度普利尤单抗在中重度未控制哮喘中的疗效和安全性。
N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
4
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.欧洲过敏研究学会/过敏标准委员会/欧洲皮肤病学会/世界变态反应组织荨麻疹指南：定义、分类、诊断和管理。
Allergy. 2018 Jul;73(7):1393-1414. doi: 10.1111/all.13397.
5
Care pathways for the selection of a biologic in severe asthma.重度哮喘生物制剂选择的照护路径
Eur Respir J. 2017 Dec 7;50(6). doi: 10.1183/13993003.01782-2017. Print 2017 Dec.
Zotero 插件